Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy.

ABSTRACT:

Purpose

Prior studies have suggested the biomarker potential of plasma-derived ctDNA in patients with cancer treated with immune checkpoint inhibitors. This study investigated the ability of ctDNA to predict progression-free and overall survival in a cohort of patients with advanced cancer treated with immunotherapies.

Experimental design

In order to characterize the potential role of ultrasensitive ctDNA detection in the management of these patients, we have performed tumor whole-genome sequencing-informed, ultrasensitive ctDNA analysis-tracking approximately 1,800 tumor-specific mutations per patient-in a retrospective cohort (n = 136) and a prospective validation cohort (n = 66) across 24 cancer types treated with immune checkpoint inhibitors alone or in combination with

SUBMITTER: Garralda E 

PROVIDER: S-EPMC12809116 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature